Compared to Ca-TAT/control siRNA treatment, Ca-TAT delivery of either CCL2 siRNAs reduced HMGB1 in the primary tumor by over 75% (Figure 4C), further demonstrating increased necrosis in the primary tumor with CCL2 gene silencing. Here, HMGB1 is linked to neoplasm.